Literature DB >> 15836500

Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies.

L Lim1, P Gibbs, D Yip, J D Shapiro, R Dowling, D Smith, A Little, W Bailey, M Liechtenstein.   

Abstract

AIM: To prospectively evaluate the efficacy and safety of Selective Internal Radiation (SIR) Spheres (Sirtex Medical, Sydney, NSW, Australia) in patients with unresectable primary or secondary hepatic malignancies.
METHODS: We report our experience of SIR sphere therapy at three Australian centres. Patients with previously untreated colorectal cancer (CRC) received concurrent 5FU, other patients with CRC received 5-FU at investigator discretion and all other patients received SIR spheres alone.
RESULTS: Forty-six patients were enrolled between January 2002 and June 2003. The majority (32 patients) had metastatic colorectal cancer and five patients had hepatocellular carcinoma. The median age of patients was 64 years (range 46-78 years). Forty-three patients were evaluable for response. There were 12 partial responses, of which 10 were in patients with CRC. The median duration of response for all patients was 8.6 months (range 2-21 months). Overall treatment related toxicity was acceptable. Significant late toxicity included four cases of severe gastric ulceration, despite standard work-up and treatment by experienced interventional radiologists.
CONCLUSION: In this series of patients, treatment with SIR-spheres has demonstrated modest activity, mostly observed in patients with CRC. Toxicity was substantial in a small number of patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15836500     DOI: 10.1111/j.1445-5994.2005.00789.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  16 in total

1.  Dose delivery estimated by bremsstrahlung imaging and partition model correlated with response following intra-arterial radioembolization with 32P-glass microspheres for the treatment of hepatocellular carcinoma.

Authors:  Xiao-Dong Wang; Ren-Jie Yang; Xi-Cai Cao; Jian Tan; Bin Li
Journal:  J Gastrointest Surg       Date:  2010-03-12       Impact factor: 3.452

Review 2.  Gastroduodenal ulceration associated with radioembolization for the treatment of hepatic tumors: an institutional experience and review of the literature.

Authors:  Steven Naymagon; Richard R P Warner; Kalpesh Patel; Noam Harpaz; Josef Machac; Joshua L Weintraub; Michelle K Kim
Journal:  Dig Dis Sci       Date:  2010-03-03       Impact factor: 3.199

3.  Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver.

Authors:  Robert J Lewandowski; Riad Salem
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

4.  Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.

Authors:  M A D Vente; M Wondergem; I van der Tweel; M A A J van den Bosch; B A Zonnenberg; M G E H Lam; A D van Het Schip; J F W Nijsen
Journal:  Eur Radiol       Date:  2008-11-07       Impact factor: 5.315

5.  Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol.

Authors:  Shahram Akhlaghpoor; Alireza Aziz-Ahari; Mahasti Amoui; Shahnaz Tolooee; Hossein Poorbeigi; Shahab Sheybani
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

Review 6.  Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors.

Authors:  Andrew Kuei; Sammy Saab; Sung-Ki Cho; Stephen T Kee; Edward Wolfgang Lee
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

7.  Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres.

Authors:  T F Jakobs; S Saleem; B Atassi; E Reda; R J Lewandowski; V Yaghmai; F Miller; R K Ryu; S Ibrahim; K T Sato; L M Kulik; M F Mulcahy; R Omary; R Murthy; M F Reiser; R Salem
Journal:  Dig Dis Sci       Date:  2008-01-31       Impact factor: 3.199

8.  Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience.

Authors:  Niraj J Gusani; Fady K Balaa; Jennifer L Steel; David A Geller; J Wallis Marsh; Albert B Zajko; Brian I Carr; T Clark Gamblin
Journal:  J Gastrointest Surg       Date:  2007-09-11       Impact factor: 3.452

Review 9.  Metastatic colorectal cancer-past, progress and future.

Authors:  Kathryn Field; Lara Lipton
Journal:  World J Gastroenterol       Date:  2007-07-28       Impact factor: 5.742

Review 10.  Liver-directed therapies for patients with primary liver cancer and hepatic metastases.

Authors:  Cletus A Arciero; Elin R Sigurdson
Journal:  Curr Treat Options Oncol       Date:  2006-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.